R&G PharmaStudies Co. Ltd. A Capital Reinvestment Ratio
R&G PharmaStudies Co. Ltd. A capital reinvestment ratio. R&G PharmaStudies Co. Ltd. A (301333) has a Capital Reinvestment Ratio of 0.13x as of June 2022, meaning it reinvests 0% of its operating cash flow (CN¥40.98 Million) in capital expenditures (CN¥5.24 Million). Check 301333 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of R&G PharmaStudies Co. Ltd. A (2019–2025)
Capital reinvestment ratio of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. This chart tracks R&G PharmaStudies Co. Ltd. A's Capital Reinvestment Ratio across 7 annual periods. Also explore R&G PharmaStudies Co. Ltd. A (301333) net asset momentum to track the company's year-over-year net asset growth rate.
R&G PharmaStudies Co. Ltd. A Capital Reinvestment Ratio by Year (2019–2025)
R&G PharmaStudies Co. Ltd. A capital reinvestment ratio by year from 2019 to 2025. For the full cash flow conversion analysis, see 301333 cash generation efficiency.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.17x | CN¥114.20 Million | CN¥19.28 Million | ▲ +30.7% |
| 2024 | 0.13x | CN¥154.76 Million | CN¥19.98 Million | ▲ +25.1% |
| 2023 | 0.10x | CN¥192.56 Million | CN¥19.88 Million | ▼ -35.3% |
| 2022 | 0.16x | CN¥130.47 Million | CN¥20.83 Million | ▼ -52.2% |
| 2021 | 0.33x | CN¥114.57 Million | CN¥38.28 Million | ▼ -42.2% |
| 2020 | 0.58x | CN¥44.10 Million | CN¥25.48 Million | ▲ +129.9% |
| 2019 | 0.25x | CN¥103.48 Million | CN¥26.00 Million | — |